NCT03232203View on ClinicalTrials.gov

Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)

CompletedOBSERVATIONAL
Enrollment

16

Participants

Timeline

Start Date

April 12, 2018

Primary Completion Date

June 25, 2021

Study Completion Date

June 25, 2021

Conditions
Severe Combined Immunodeficiency Due to ADA Deficiency
Interventions
DRUG

STRIMVELIS

It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study

Trial Locations (1)

20132

Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET), Milan

All Listed Sponsors
lead

Fondazione Telethon

OTHER

NCT03232203 - Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs) | Biotech Hunter | Biotech Hunter